We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MAB Discovery Enters Into an Agreement with Top 20 Global Pharma Company
Product News

MAB Discovery Enters Into an Agreement with Top 20 Global Pharma Company

MAB Discovery Enters Into an Agreement with Top 20 Global Pharma Company
Product News

MAB Discovery Enters Into an Agreement with Top 20 Global Pharma Company


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MAB Discovery Enters Into an Agreement with Top 20 Global Pharma Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MAB Discovery has announced that they have initiated two independent research collaborations with a US oncology focused biotech and a top 20 pharmaceutical company.

Employing its unique discovery platform, MAB Discovery will deliver a number of monoclonal antibodies to partner selected targets. Financial terms were not disclosed in either case.

MAB Discovery employs natural immunization of wild type animals (rabbits and rats), followed by fully automated single B cell cloning and PCR methods to discover high affinity monoclonals covering extensive epitope space.

Large and diverse panels of antibodies are created from B cells isolated at various times post immunization.

The power of the MAB Discovery platform resides in the vast number of high quality monoclonals from which to choose candidates with desired specificity and functionality.

In the case of rabbits, which have been well recognized over the years as excellent sources of high quality antibodies to virtually any antigen, the derived monoclonals are of extreme high affinity (<1nM), obviating the need for time-consuming affinity maturation campaigns with uncertain outcomes.

Applications for the MAB Discovery platform range from discovery of monoclonals to novel and difficult targets (eg, GPCRs, ion channels), to finding agents suitable for ADC strategies, to making "biobetters", etc.

"I am very pleased with the speed and efficiency by which our CEO, Dr. Stephan Fischer, and his team have been able to establish and validate the platform and to launch these important collaborations", said Dr. Lee Babiss, Chairman of MAB Discovery and CSO of PPD.

Dr. Babiss continued, "Companies such as MAB Discovery are positioned to take advantage of the increased outsourcing of discovery by large pharmas."

Advertisement